BETA
Indiana-based developer of renal medical devices and therapeutics, including an investigational acute kidney injury system, MorCor biopsy technology and polycystic kidney disease programs.
Restari is a privately held company founded in 2022 by CEO Matt Hedrick and Chief Medical Officer Robert Bacallao. Its company LinkedIn lists headquarters in Indianapolis, Indiana, United States; its research laboratories are at the Indiana Biosciences Research Institute in Indianapolis. The company combines renal device development, biopsy technology and pharmaceutical research.
Its investigational acute kidney injury system is designed to deliver controlled fluid pulses through a specialized venous catheter. Restari describes the program as in late-stage clinical development and states that it is not approved by any regulatory agency. Public evidence reviewed includes preclinical rat research; a corresponding human trial identifier and results were not independently verified. MorCor, a full-core biopsy technology, is listed as coming soon.
In February 2026, Restari announced an exclusive license and commercialization agreement with AriBio for a small-molecule program targeting certain polycystic kidney and cystic liver diseases. The agreement provides rights in agreed territories outside AriBio’s retained regions and includes contingent milestone and royalty economics. It is not a financing round. Restari also describes discovery-stage kidney gene-therapy work; revenue, funding totals and named commercial deployments were not verified.
Restari’s acute-kidney-injury device remains unapproved according to the company. No product-matched FDA marketing decision was established for that system or the MorCor biopsy technology. Its renal small-molecule and gene-therapy programs require separate drug/biologic review; another company’s Alzheimer’s trial is not evidence of Restari’s renal development stage. [18][12][1]
No matching FDA recall event was identified in the completed company/applicant, linked-identifier and product-name searches. [5][3]
Latest recorded source review: 2026-10-20.
Scope: selected product families.
No commercially marketed product portfolio has been established in the reviewed material.
Company-described system delivers controlled fluid pulses through a specialized venous catheter, intended to improve renal microvascular perfusion. [16][8]
Investigational / in developmentInvestigational. Company states late-stage clinical development; exact trial phase and human results not independently verified.
Full-core sampling technology in Restari’s announced biopsy portfolio, intended to collect larger, less fragmented specimens. Comparative claims rely on company data on file. [17][7][20]
Investigational / in developmentComing soon on current Restari biopsy page; completed launch and commercial availability not verified.
Licensed AriBio program for certain polycystic kidney and cystic liver disease indications. Restari separately describes a once-daily oral development approach. [12][19]
Investigational / in developmentIn development under announced licensing agreement; no marketed renal or hepatic indication established.
Explores direct renal gene delivery using the AKI device platform. Website presents animal gene-delivery research as a technical foundation. [19]
Investigational / in developmentDiscovery-stage research, not commercially available.
Restari announced exclusive development and commercialization rights for a small-molecule PKD and cystic liver disease program in agreed territories outside AriBio’s retained regions. Terms include contingent milestones and royalties; no capital raise inferred. [12]
Company founding year is 2022, corroborated by company-issued license announcement and LinkedIn. [11]
Accessed 10/20/2026